Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/bimzelx-48-week-phase-3-analyses-in-moderate-to-severe-hidradenitis-suppurativa-showed-sustained-improvements-in-skin-pain-and-draining-tunnel-count-302083639.html
https://www.fiercepharma.com/pharma/seeking-blockbuster-status-ucb-eyes-four-new-indications-psoriasis-med-bimzelx-2024
https://www.prnewswire.com/news-releases/ucb-on-growth-path-for-a-decade-plus-302073984.html
https://www.prnewswire.com/news-releases/ucb-presents-late-breaking-posters-at-child-neurology-society-meeting-301947405.html
https://www.fiercepharma.com/pharma/ucbs-bimekizumab-remains-fda-limbo-agency-closes-inspection
https://www.fiercepharma.com/pharma/lundbeck-replaces-retiring-ceo-dunsire-ucb-exec-after-breaking-sales-record
https://www.pharmaceutical-technology.com/news/ariceum-ucb-therapies-cancer/
https://www.fiercepharma.com/pharma/ucbs-bimekizumab-proves-longer-outcomes-hidradenitis-suppurativa
http://www.pharmatimes.com/news/ucbs_bimekizumab_issued_nice_recommendation_for_severe_plaque_psoriasis_1373966